8-K
filed June 20, 2023, 7:59 PM ET
ticker ALXO
CIK 0001810182
other
confidence high
sentiment neutral
materiality 0.20
ALX Oncology amends bylaws and announces annual meeting voting results
ALX ONCOLOGY HOLDINGS INC
- Board approved amended bylaws effective June 17, 2023, enhancing stockholder nomination procedures and complying with universal proxy rules and Delaware law.
- Three Class III directors elected: Scott Garland (35.7M for), Rekha Hemrajani (31.9M for), Jaume Pons (35.6M for), all to serve until 2026.
- Advisory vote on named executive officer compensation passed (35.5M for, 413K against, 9K abstain).
- Ratification of KPMG as independent auditor for FY2023 approved (38.5M for, 8.8K against, 3K abstain).
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
ALX ONCOLOGY HOLDINGS INC: Amended and restated bylaws to enhance stockholder nomination and proposal procedures, revise stockholder meeting provisions, update director/committee/officer provisions, and conform to Delaware law (effective 2023-06-17).
- Change
- bylaw amendment
- Effective
- 2023-06-17
Exact text from the filing
On June 16, 2023, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Bylaws”) effective as of June 17, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ALX ONCOLOGY HOLDINGS INC shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 38,518,146 8,803 3,009 The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ALX ONCOLOGY HOLDINGS INC shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2023-06-16 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers For Against Abstain Broker Non-Votes 35,476,558 413,798 9,213 2,630,389 The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ALX ONCOLOGY HOLDINGS INC shareholders approved Election of Three Class III Directors at the 2023-06-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Proposal 1: Election of Three Class III Directors Name of Director For Withheld Broker Non-Votes Scott Garland 35,698,803 200,766 2,630,389 Rekha Hemrajani 31,953,951 3,945,618 2,630,389 Jaume Pons, Ph.D. 35,591,034 308,535 2,630,389 Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.